Report published September 23, 2026
The China Report: Trump-Xi Summit - Expect Optics, Not Outcomes – TD Cowen Research
TD Cowen · September 23, 2026
TD Cowen views the September 2026 Trump-Xi summit as a 'process meeting' focused on optics and strategic stability rather than substantive policy breakthroughs. The most likely deliverable is an extension of the Busan trade truce alongside modest purchasing headlines, leaving core structural tensions in technology, defense, and biopharma unresolved.
Read the remaining 4 pages
Finvaulta summarizes TD Cowen's analysis. Attribute opinions, forecasts, time-sensitive values, and chronology to the issuer and report date; do not treat this page as an independent verification or a current market-data source.
Key Takeaways
- 1.The Trump-Xi summit in Washington is a 'process meeting' aimed at establishing strategic stability and dispute management rather than delivering comprehensive trade or security breakthroughs.
- 2.Extending the Busan trade truce beyond November 10 represents the most realistic economic deliverable, alongside incremental agricultural, Boeing aircraft, and fossil fuel (LNG) commitments.
- 3.Export control risks surrounding semicap equipment (MATCH Act) and advanced AI GPU licensing (AI Diffusion rule) present headline risk but are unlikely to severely disrupt affected chip companies.
Table of Contents
- Macro Policy – Chris Krueger
- Geopolitics & Defense – Roman Schweizer
- TMT Policy Outlook – Paul Gallant
- Health Care – Molly Turco / Erin McAllister
- But Biopharmas Are Relying More On PRC For Innovation
- Energy Transition – John Miller
- Financial Services & Housing Policy – Jaret Seiberg
Report data
Figure 1 PRC As A Source Of Critical Medicines & Biopharma Innovation Is A Going Concern In Washington
| Metric | Estimate | Context |
|---|---|---|
| Busan Trade Truce Expiration Date | 2026-11-10 | The scheduled expiration date of the US-China trade truce agreed upon in Busan, Korea in October 2025 absent an extension. |
| Biopharma Manufacturing Infrastructure Commitments | 600.0 USD Billion | Committed US manufacturing infrastructure investments in President Trump's MFN deals with biopharma companies. |
| DOD Biotechnology Domestic Manufacturing Investments | 962.5 USD Million | Total DOD investment across three initiatives to support biotechnology and establish domestic biomanufacturing supply chains. |
| Chinese Government Guidance Funds for Emerging Tech | 1.0 USD Trillion | Capital invested by Chinese Government Guidance Funds to scale up emerging technologies including biotech and pharma. |
| Cumulative NIH Funding | 481.0 USD Billion | Cumulative total US funding for the National Institutes of Health compared to Chinese Guidance Funds over the same 10-year period. |
Access the full report
And others from the leading tier 1 banks.
Free account: read previews and a daily allowance of full reports. Pro removes the daily limit.